Find clinical trials for Multiple Myeloma in Louisville, KY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer

Hematologic Cancer

Lymphoma

Cancer

Leukemia

Smoldering Multiple Myeloma

Non-Hodgkin Lymphoma

Multiple Myeloma trials near Louisville, KY, USA:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting

Multiple Myeloma

Drug: Daratumumab

Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)

Louisville, Kentucky, United States and 145 other locations

Locations recently updated

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, i...

Enrolling

Multiple Myeloma

Drug: Fludarabine

Drug: Cyclophosphamide

Phase 3

Gilead Sciences

Shelbyville, Kentucky, United States and 6 other locations

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling

Multiple Myeloma

Biological: BMS-986393

Phase 2

Juno Therapeutics

Saint Matthews, Kentucky, United States and 46 other locations

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...

Active, not recruiting

Multiple Myeloma

Drug: Dexamethasone

Drug: Daratumumab

Phase 2

Celgene

Louisville, Kentucky, United States and 48 other locations

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with MM r...

Active, not recruiting

Multiple Myeloma

Drug: Dexamethasone

Drug: Eftozanermin alfa

Phase 1

AbbVie

Louisville, Kentucky, United States and 18 other locations

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding o ...

Active, not recruiting

Multiple Myeloma

Drug: Elranatamab (PF-06863135)

Phase 2

Pfizer

Louisville, Kentucky, United States and 78 other locations

Locations recently updated

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...

Enrolling

Multiple Myeloma

Drug: Linvoseltamab

Phase 1, Phase 2

Regeneron Pharmaceuticals

Louisville, Kentucky, United States and 27 other locations

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling

Multiple Myeloma

Drug: Bortezomib

Drug: Daratumumab

Phase 3

Celgene

Louisville, Kentucky, United States and 278 other locations

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting

Multiple Myeloma

Drug: Pomalidomide

Drug: Venetoclax

Phase 3

AbbVie

Louisville, Kentucky, United States and 180 other locations

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Active, not recruiting

Multiple Myeloma

Drug: Lenalidomide

Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)

Louisville, Kentucky, United States and 135 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Multiple Myeloma in .css-epvm6{white-space:nowrap;}Louisville, KY

Related conditions:

Multiple Myeloma trials near Louisville, KY, USA:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting (POM MM 014)

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment (LINKER-MM4)

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Find clinical trials for Multiple Myeloma in Louisville, KY